Cite
HARVARD Citation
Doria, A. et al. (2018). Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. Arthritis & rheumatology. 70 (8), pp. 1256-1264. [Online].